Paradigm Therapeutics

Associate Sponsor

Paradigm Therapeutics is a Charleston-based biotechnology company clinical-stage company advancing SD-101-6.0 (Zorblesia), a first-in-class topical therapy for Epidermolysis Bullosa (EB) across all subtypes, a devastating condition characterized by extreme skin fragility and chronic infection risk.  As the only treatment in development for the entire skin surface across all EB subtypes, SD-101-6.0 addresses a critical unmet need for patients with "butterfly skin."

SD-101-6.0 was the first therapy to receive FDA Breakthrough Therapy designation for EB and is the only candidate currently designed to treat the whole skin surface across all disease subtypes. Extensive Phase 2 and 3 clinical data demonstrate a robust safety and tolerability profile with average usage exceeding two years. Paradigm is currently fast-tracking this late-stage therapy to provide a systemic solution for a community with significant manifestations associated with the disease.

Beyond its clinical impact, the program is positioned for high-value commercialization, with eligibility for a Rare Pediatric Disease Priority Review Voucher (PRV)—an asset currently valued at $175+M in the secondary market.

website